Don't Overlook These Top Medical Stocks as Q1 Earnings Approach

Zacks05-07

Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433262482?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644","is_english":true,"pubTime":"2024-05-07 07:57","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2433262482","market":"us","top_or_hot":-1,"title":"Don't Overlook These Top Medical Stocks as Q1 Earnings Approach","media":"Zacks","content":"<div>\n<p>Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings...</p>\n\n<a href=\"https://finance.yahoo.com/news/dont-overlook-top-medical-stocks-235700037.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Don't Overlook These Top Medical Stocks as Q1 Earnings Approach</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDon't Overlook These Top Medical Stocks as Q1 Earnings Approach\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-07 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/dont-overlook-top-medical-stocks-235700037.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings...</p>\n\n<a href=\"https://finance.yahoo.com/news/dont-overlook-top-medical-stocks-235700037.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/dont-overlook-top-medical-stocks-235700037.html","article_id":"2433262482","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433262482","pubTimestamp":1715039820,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings contribution of the Mag 7, Q1 earnings growth for the rest of the S&P 500 index would be in negative territory.That said, several top-rated Zacks Medical sector stocks are standing out ahead of their Q1 reports on Tuesday, May 7. With now looking like an ideal to invest in their growth, here are three of these top healthcare companies to consider as earnings approach.Focused on the development and licensing of biopharmaceutical assets, Ligand Pharmaceuticals has been able to enter several licensing deals and generate royalties through its Captisol formulation technology which improves the safety and overall use of drugs including their solubility, bioavailability, smell, and taste.While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc.","OSCR":"Oscar Health, Inc."},"translate_title":"随着Q1收益的临近，不要忽视这些顶级医疗股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":0.9,"OSCR":0.9},"content_text":"Thanks to the Magnificent Seven, tech stocks have led the Q1 earnings season. In fact, as Sheraz Mian the Director of Zacks Investment Research points out, had it not been for the substantial earnings contribution of the Mag 7, Q1 earnings growth for the rest of the S&P 500 index would be in negative territory.\nThat said, several top-rated Zacks Medical sector stocks are standing out ahead of their Q1 reports on Tuesday, May 7. With now looking like an ideal to invest in their growth, here are three of these top healthcare companies to consider as earnings approach.\nLigand Pharmaceuticals LGND\nZacks Rank #1 (Strong Buy)\nFocused on the development and licensing of biopharmaceutical assets, Ligand Pharmaceuticals has been able to enter several licensing deals and generate royalties through its Captisol formulation technology which improves the safety and overall use of drugs including their solubility, bioavailability, smell, and taste.\nLigand Pharmaceuticals’ Q1 earnings are expected at $1.13 a share following a very tough-to-compete against prior year quarter that saw EPS at $2.28. Still, annual earnings are projected to jump 12% this year and are forecasted to climb another 15% in fiscal 2025 to $5.27 per share. More compelling and attributing to Ligand Pharmaceuticals strong buy rating is that earnings estimates for the current quarter, FY24, and FY25 are noticeably higher over the last 60 days.\nImage Source: Zacks Investment Research\nOscar Health OSCR\nZacks Rank #2 (Buy)\nAs a digital health insurance company, Oscar Health’s top line growth is hard to overlook and suggests the company should be very profitable down the line after going public in 2021. Trading under $20 a share, the risk to reward looks favorable to invest in Oscar Health's stock with Q1 sales thought to have climbed 33% to $1.96 billion versus $1.47 billion in the comparative quarter.\nEven better, Q1 EPS is expected at $0.28 compared to an adjusted loss of -$0.18 a share in the prior-year quarter. More impressive, total sales are now projected to soar 43% in FY24 and are slated to climb another 20% in FY25 to $10.08 billion. Plus, Oscar Health is expected to turn its first annual earnings profit next year.at $0.42 a share.\nImage Source: Zacks Investment Research\nPenumbra PEN\nZacks Rank #2 (Buy)\nWith a very attractive growth trajectory, Penumbra is a global healthcare company offering innovative products for the neurovascular, vascular, and neurosurgical markets. Penumbra’s Q1 earnings are expected to soar 82% to $0.42 a share with sales expected to rise 14% to $274.82 million.\nBetter still, Penumbra is projected to post high double-digit percentage growth on its top and bottom lines in FY24 and FY25.   \nImage Source: Zacks Investment Research\nTakeaway\nWhile the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and Penumbra is hard to ignore and now looks like an ideal time to buy as they are shaping up to be viable investments for 2024 and beyond.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nOscar Health, Inc. (OSCR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433262482"}